Skip to main content
Top
Published in: Critical Care 5/2014

Open Access 01-10-2014 | Review

Management of pulmonary vasodilator therapy in patients with pulmonary arterial hypertension during critical illness

Authors: Katie M Muzevich, Hadi Chohan, Daniel C Grinnan

Published in: Critical Care | Issue 5/2014

Login to get access

Abstract

Pulmonary arterial hypertension (PAH) is commonly treated with pulmonary arteriolar vasodilator therapy. When a patient on PAH medication is admitted to intensive care, determining how to manage their medication during the critical illness is often complicated. There may be considerations related to the inability to take medication by mouth, related to acute renal failure or acute liver injury, related to altered mental status or delirium, or related to hypotension and bacteremia. Decisions of how to manage these medications can have a major impact on the patient’s clinical course. Presently, provider experience is the major tool in navigating the decisions regarding these medications. In this review, we offer our recommendations of how to manage PAH patients with critical illness who are on PAH medications. These recommendations include how to deliver medications via feeding tubes, how to dose medications in the setting of acute renal failure or acute liver failure, and how to manage medications during hypotension or when a tunneled catheter needs to be removed.
Appendix
Available only for authorised users
Literature
1.
go back to reference Grinnan DC, Swetz KM, Pinson J, Fairman P, Lyckholm LJ, Smith T: The end-of-life experience for a cohort of patients with pulmonary arterial hypertension. J Palliat Med. 2012, 15: 1065-1070. 10.1089/jpm.2012.0085.CrossRef Grinnan DC, Swetz KM, Pinson J, Fairman P, Lyckholm LJ, Smith T: The end-of-life experience for a cohort of patients with pulmonary arterial hypertension. J Palliat Med. 2012, 15: 1065-1070. 10.1089/jpm.2012.0085.CrossRef
2.
go back to reference Tonelli AR, Arelli V, Minai OA, Newman J, Bair N, Heresi GA, Dweik RA: Causes and circumstances of death in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2013, 188: 365-369. 10.1164/rccm.201209-1640OC.CrossRef Tonelli AR, Arelli V, Minai OA, Newman J, Bair N, Heresi GA, Dweik RA: Causes and circumstances of death in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2013, 188: 365-369. 10.1164/rccm.201209-1640OC.CrossRef
3.
go back to reference D’Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, Fishman AP, Goldring RM, Groves BM, Kernis JT: Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med. 1991, 115: 343-349. 10.7326/0003-4819-115-5-343.CrossRef D’Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, Fishman AP, Goldring RM, Groves BM, Kernis JT: Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med. 1991, 115: 343-349. 10.7326/0003-4819-115-5-343.CrossRef
4.
go back to reference Benza RL, Miller DP, Barst RJ, Badesch DB, Frost AE, McGoon MD: An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest. 2012, 142: 448-456. 10.1378/chest.11-1460.CrossRef Benza RL, Miller DP, Barst RJ, Badesch DB, Frost AE, McGoon MD: An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest. 2012, 142: 448-456. 10.1378/chest.11-1460.CrossRef
5.
go back to reference Hoeper MM, Granton J: Intensive care unit management of patients with severe pulmonary hypertension and right heart failure. Am J Respir Crit Care Med. 2011, 184: 1114-1124. 10.1164/rccm.201104-0662CI.CrossRef Hoeper MM, Granton J: Intensive care unit management of patients with severe pulmonary hypertension and right heart failure. Am J Respir Crit Care Med. 2011, 184: 1114-1124. 10.1164/rccm.201104-0662CI.CrossRef
6.
go back to reference Dellinger RP, Trzeciak SW, Criner GJ, Zimmerman JL, Taylor RW, Usansky H, Young J, Goldstein B: Association between inhaled nitric oxide treatment and long-term pulmonary function in survivors of acute respiratory distress syndrome. Crit Care. 2012, 16: R36-10.1186/cc11215.CrossRef Dellinger RP, Trzeciak SW, Criner GJ, Zimmerman JL, Taylor RW, Usansky H, Young J, Goldstein B: Association between inhaled nitric oxide treatment and long-term pulmonary function in survivors of acute respiratory distress syndrome. Crit Care. 2012, 16: R36-10.1186/cc11215.CrossRef
7.
go back to reference Williams NT: Medication administration through enteral feeding tubes. Am J Health Syst Pharm. 2008, 65: 2347-2357. 10.2146/ajhp080155.CrossRef Williams NT: Medication administration through enteral feeding tubes. Am J Health Syst Pharm. 2008, 65: 2347-2357. 10.2146/ajhp080155.CrossRef
8.
go back to reference Revatio (Sildenafil) Product Monograph. New York, NY: Pfizer Laboratories Div Pfizer Inc; 2012. Revatio (Sildenafil) Product Monograph. New York, NY: Pfizer Laboratories Div Pfizer Inc; 2012.
9.
go back to reference Apitz C, Reyes JT, Holtby H, Humpl T, Redington AN: Pharmacokinetic and hemodynamic responses to oral sildenafil during invasive testing in children with pulmonary hypertension. J Am Coll Cardiol. 2010, 55: 1456-1462. 10.1016/j.jacc.2009.11.065.CrossRef Apitz C, Reyes JT, Holtby H, Humpl T, Redington AN: Pharmacokinetic and hemodynamic responses to oral sildenafil during invasive testing in children with pulmonary hypertension. J Am Coll Cardiol. 2010, 55: 1456-1462. 10.1016/j.jacc.2009.11.065.CrossRef
10.
go back to reference Hon KL, Cheung KL, Siu KL, Leung TF, Yam MC, Fok TF, Ng PC: Oral sildenafil for treatment of severe pulmonary hypertension in an infant. Biol Neonate. 2005, 88: 109-112. 10.1159/000085646.CrossRef Hon KL, Cheung KL, Siu KL, Leung TF, Yam MC, Fok TF, Ng PC: Oral sildenafil for treatment of severe pulmonary hypertension in an infant. Biol Neonate. 2005, 88: 109-112. 10.1159/000085646.CrossRef
11.
go back to reference Adcirca (Tadalafil) Product Monograph. Indianapolis, IN: United Therapeutics Corp; 2012. Adcirca (Tadalafil) Product Monograph. Indianapolis, IN: United Therapeutics Corp; 2012.
12.
go back to reference Pettit RS, Johnson CE, Caruthers RL: Stability of an extemporaneously prepared tadalafil suspension. Am J Health Syst Pharm. 2012, 69: 592-594. 10.2146/ajhp110034.CrossRef Pettit RS, Johnson CE, Caruthers RL: Stability of an extemporaneously prepared tadalafil suspension. Am J Health Syst Pharm. 2012, 69: 592-594. 10.2146/ajhp110034.CrossRef
13.
go back to reference Tracleer (Bosentan) Product Monograph. South San Francisco, CA: Actelion Pharmaceuticals US Inc; 2012. Tracleer (Bosentan) Product Monograph. South San Francisco, CA: Actelion Pharmaceuticals US Inc; 2012.
15.
go back to reference Nakwan N, Choksuchat D, Saksawad R, Thammachote P, Nakwan N: Successful treatment of persistent pulmonary hypertension of the newborn with bosentan. Acta Paediatr. 2009, 98: 1683-1685. 10.1111/j.1651-2227.2009.01386.x.CrossRef Nakwan N, Choksuchat D, Saksawad R, Thammachote P, Nakwan N: Successful treatment of persistent pulmonary hypertension of the newborn with bosentan. Acta Paediatr. 2009, 98: 1683-1685. 10.1111/j.1651-2227.2009.01386.x.CrossRef
17.
go back to reference Letairis (Ambrisentan) Product Monograph. Foster City, CA: Gilead Sciences Inc; 2012. Letairis (Ambrisentan) Product Monograph. Foster City, CA: Gilead Sciences Inc; 2012.
18.
go back to reference Opsumit (Macitentan) Product Monograph. South San Francisco, CA: Actelion Pharmaceuticals US Inc; 2013. Opsumit (Macitentan) Product Monograph. South San Francisco, CA: Actelion Pharmaceuticals US Inc; 2013.
19.
go back to reference Adempas (Riociguat) Product Monograph. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc; 2013. Adempas (Riociguat) Product Monograph. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc; 2013.
20.
go back to reference Ventavis (Iloprost) Product Monograph. South San Francisco, CA: Actelion Pharmaceuticals US Inc; 2012. Ventavis (Iloprost) Product Monograph. South San Francisco, CA: Actelion Pharmaceuticals US Inc; 2012.
21.
go back to reference Tyvaso (Treprostinil) Product Monograph. Research Triangle Park, NC: United Therapeutics Corp; 2011. Tyvaso (Treprostinil) Product Monograph. Research Triangle Park, NC: United Therapeutics Corp; 2011.
22.
go back to reference Harris KW, O’Riordan TG, Smaldone GC: Aerosolized iloprost customized for the critically ill. Respir Care. 2007, 52: 1507-1509. Harris KW, O’Riordan TG, Smaldone GC: Aerosolized iloprost customized for the critically ill. Respir Care. 2007, 52: 1507-1509.
23.
go back to reference Doran AK, Ivy DD, Barst RJ, Hill N, Murali S, Benza RL: Guidelines for the prevention of central venous catheter-related blood stream infections with prostanoid therapy for pulmonary arterial hypertension. Int J Clin Pract Suppl. 2008, 160: 5-9. 10.1111/j.1742-1241.2008.01811.x.CrossRef Doran AK, Ivy DD, Barst RJ, Hill N, Murali S, Benza RL: Guidelines for the prevention of central venous catheter-related blood stream infections with prostanoid therapy for pulmonary arterial hypertension. Int J Clin Pract Suppl. 2008, 160: 5-9. 10.1111/j.1742-1241.2008.01811.x.CrossRef
24.
go back to reference Lopez-Medrano F, Fernandez-Ruiz M, Ruiz-Cano MJ, Barrios E, Vicente-Hernandez M, Aguado JM, Escribano P: High incidence of bloodstream infection due to Gram-negative bacilli in patients with pulmonary hypertension receiving intravenous treprostinil. Arch Bronconeumol. 2012, 48: 443-447. 10.1016/j.arbres.2012.06.005.CrossRef Lopez-Medrano F, Fernandez-Ruiz M, Ruiz-Cano MJ, Barrios E, Vicente-Hernandez M, Aguado JM, Escribano P: High incidence of bloodstream infection due to Gram-negative bacilli in patients with pulmonary hypertension receiving intravenous treprostinil. Arch Bronconeumol. 2012, 48: 443-447. 10.1016/j.arbres.2012.06.005.CrossRef
25.
go back to reference Gomez Sanchez MA: Infections by Gram-negative bacilli in patients with pulmonary arterial hypertension treated with intravenous prostacyclin. Arch Bronconeumol. 2013, 49: 128-129. 10.1016/j.arbres.2012.09.003.CrossRef Gomez Sanchez MA: Infections by Gram-negative bacilli in patients with pulmonary arterial hypertension treated with intravenous prostacyclin. Arch Bronconeumol. 2013, 49: 128-129. 10.1016/j.arbres.2012.09.003.CrossRef
26.
go back to reference Mermel LA, Allon M, Bouza E, Craven DE, Flynn P, O’Grady NP, Raad II, Rijnders BJ, Sherertz RJ, Warren DK: Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009, 49: 1-45. 10.1086/599376.CrossRef Mermel LA, Allon M, Bouza E, Craven DE, Flynn P, O’Grady NP, Raad II, Rijnders BJ, Sherertz RJ, Warren DK: Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009, 49: 1-45. 10.1086/599376.CrossRef
30.
go back to reference Kingman MS, Tankersley MA, Lombardi S, Spence S, Torres F, Chin KS: Prostacyclin administration errors in pulmonary arterial hypertension patients admitted to hospitals in the United States: a national survey. J Heart Lung Transplant. 2010, 29: 841-846. 10.1016/j.healun.2010.03.008.CrossRef Kingman MS, Tankersley MA, Lombardi S, Spence S, Torres F, Chin KS: Prostacyclin administration errors in pulmonary arterial hypertension patients admitted to hospitals in the United States: a national survey. J Heart Lung Transplant. 2010, 29: 841-846. 10.1016/j.healun.2010.03.008.CrossRef
31.
go back to reference Ely EW, Shintani A, Truman B, Speroff T, Gordon SM, Harrell FE, Inouye SK, Bernard GR, Dittus RS: Delirium as a predictor of mortality in mechanically ventilated patients in the intensive care unit. JAMA. 2004, 291: 1753-1762. 10.1001/jama.291.14.1753.CrossRef Ely EW, Shintani A, Truman B, Speroff T, Gordon SM, Harrell FE, Inouye SK, Bernard GR, Dittus RS: Delirium as a predictor of mortality in mechanically ventilated patients in the intensive care unit. JAMA. 2004, 291: 1753-1762. 10.1001/jama.291.14.1753.CrossRef
32.
go back to reference Preston IR, Sagliani KD, Roberts KE, Shah AM, Desouza SA, Howard W, Brennan J, Hill NS: Comparison of acute hemodynamic effects of inhaled nitric oxide and inhaled epoprostenol in patients with pulmonary hypertension. Pulm Circ. 2013, 3: 68-73. 10.4103/2045-8932.109918.CrossRef Preston IR, Sagliani KD, Roberts KE, Shah AM, Desouza SA, Howard W, Brennan J, Hill NS: Comparison of acute hemodynamic effects of inhaled nitric oxide and inhaled epoprostenol in patients with pulmonary hypertension. Pulm Circ. 2013, 3: 68-73. 10.4103/2045-8932.109918.CrossRef
33.
go back to reference Weinberger B, Laskin DL, Heck DE, Laskin JD: The toxicology of inhaled nitric oxide. Toxicol Sci. 2001, 59: 5-16. 10.1093/toxsci/59.1.5.CrossRef Weinberger B, Laskin DL, Heck DE, Laskin JD: The toxicology of inhaled nitric oxide. Toxicol Sci. 2001, 59: 5-16. 10.1093/toxsci/59.1.5.CrossRef
34.
go back to reference Haraldsson A, Kieler-Jensen N, Ricksten SE: Inhaled prostacyclin for treatment of pulmonary hypertension after cardiac surgery or heart transplantation: a pharmacodynamic study. J Cardiothorac Vasc Anesth. 1996, 10: 864-868. 10.1016/S1053-0770(96)80047-4.CrossRef Haraldsson A, Kieler-Jensen N, Ricksten SE: Inhaled prostacyclin for treatment of pulmonary hypertension after cardiac surgery or heart transplantation: a pharmacodynamic study. J Cardiothorac Vasc Anesth. 1996, 10: 864-868. 10.1016/S1053-0770(96)80047-4.CrossRef
35.
go back to reference Buckley MS, Feldman JP: Inhaled epoprostenol for the treatment of pulmonary arterial hypertension in critically ill adults. Pharmacotherapy. 2010, 30: 728-740. 10.1592/phco.30.7.728.CrossRef Buckley MS, Feldman JP: Inhaled epoprostenol for the treatment of pulmonary arterial hypertension in critically ill adults. Pharmacotherapy. 2010, 30: 728-740. 10.1592/phco.30.7.728.CrossRef
36.
go back to reference Siobal MS, Kallet RH, Pittet JF, Warnecke EL, Kraemer RW, Venkayya RV, Tang JF: Description and evaluation of a delivery system for aerosolized prostacyclin. Respir Care. 2003, 48: 742-753. Siobal MS, Kallet RH, Pittet JF, Warnecke EL, Kraemer RW, Venkayya RV, Tang JF: Description and evaluation of a delivery system for aerosolized prostacyclin. Respir Care. 2003, 48: 742-753.
37.
go back to reference Uchino S, Kellum JA, Bellomo R, Doig GS, Morimatsu H, Morgera S, Schetz M, Tan I, Bouman C, Macedo E, Gibney N, Tolwani A, Ronco C: Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA. 2005, 294: 813-818. 10.1001/jama.294.7.813.CrossRef Uchino S, Kellum JA, Bellomo R, Doig GS, Morimatsu H, Morgera S, Schetz M, Tan I, Bouman C, Macedo E, Gibney N, Tolwani A, Ronco C: Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA. 2005, 294: 813-818. 10.1001/jama.294.7.813.CrossRef
38.
go back to reference Mielniczuk LM, Chandy G, Stewart D, Contreras-Dominguez V, Haddad H, Pugliese C, Davies RA: Worsening renal function and prognosis in pulmonary hypertension patients hospitalized for right heart failure. Congest Heart Fail. 2012, 18: 151-157. 10.1111/j.1751-7133.2011.00275.x.CrossRef Mielniczuk LM, Chandy G, Stewart D, Contreras-Dominguez V, Haddad H, Pugliese C, Davies RA: Worsening renal function and prognosis in pulmonary hypertension patients hospitalized for right heart failure. Congest Heart Fail. 2012, 18: 151-157. 10.1111/j.1751-7133.2011.00275.x.CrossRef
39.
go back to reference Flolan (Epoprostenol) Product Monograph. Research Triangle Park, NC: GlaxoSmithKline; 2011. Flolan (Epoprostenol) Product Monograph. Research Triangle Park, NC: GlaxoSmithKline; 2011.
40.
go back to reference Veletri (Epoprostenol) Product Monograph. South San Francisco, CA: Actelion Pharmaceuticals US Inc; 2011. Veletri (Epoprostenol) Product Monograph. South San Francisco, CA: Actelion Pharmaceuticals US Inc; 2011.
41.
go back to reference Remodulin (Treprostinil) Product Monograph. Research Triangle Park, NC: United Therapeutics Corp; 2012. Remodulin (Treprostinil) Product Monograph. Research Triangle Park, NC: United Therapeutics Corp; 2012.
42.
go back to reference INOmax (Nitric Oxide) Product Monograph. Hampton, NJ: INO Therapeutics; 2011. INOmax (Nitric Oxide) Product Monograph. Hampton, NJ: INO Therapeutics; 2011.
43.
go back to reference Thomson SJ, Cowan ML, Johnston I, Musa S, Grounds M, Rahman TM: `Liver function tests’ on the intensive care unit: a prospective, observational study. Intensive Care Med. 2009, 35: 1406-1411. 10.1007/s00134-009-1511-7.CrossRef Thomson SJ, Cowan ML, Johnston I, Musa S, Grounds M, Rahman TM: `Liver function tests’ on the intensive care unit: a prospective, observational study. Intensive Care Med. 2009, 35: 1406-1411. 10.1007/s00134-009-1511-7.CrossRef
44.
go back to reference Mesotten D, Wauters J, Van den Berghe G, Wouters PJ, Milants I, Wilmer A: The effect of strict blood glucose control on biliary sludge and cholestasis in critically ill patients. J Clin Endocrinol Metab. 2009, 94: 2345-2352. 10.1210/jc.2008-2579.CrossRef Mesotten D, Wauters J, Van den Berghe G, Wouters PJ, Milants I, Wilmer A: The effect of strict blood glucose control on biliary sludge and cholestasis in critically ill patients. J Clin Endocrinol Metab. 2009, 94: 2345-2352. 10.1210/jc.2008-2579.CrossRef
45.
go back to reference Fuhrmann V, Kneidinger N, Herkner H, Heinz G, Nikfardjam M, Bojic A, Schellongowski P, Angermayr B, Schoniger-Hekele M, Madl C, Schenk P: Impact of hypoxic hepatitis on mortality in the intensive care unit. Intensive Care Med. 2011, 37: 1302-1310. 10.1007/s00134-011-2248-7.CrossRef Fuhrmann V, Kneidinger N, Herkner H, Heinz G, Nikfardjam M, Bojic A, Schellongowski P, Angermayr B, Schoniger-Hekele M, Madl C, Schenk P: Impact of hypoxic hepatitis on mortality in the intensive care unit. Intensive Care Med. 2011, 37: 1302-1310. 10.1007/s00134-011-2248-7.CrossRef
46.
go back to reference Lescot T, Karvellas C, Beaussier M, Magder S: Acquired liver injury in the intensive care unit. Anesthesiology. 2012, 117: 898-904. 10.1097/ALN.0b013e318266c6df.CrossRef Lescot T, Karvellas C, Beaussier M, Magder S: Acquired liver injury in the intensive care unit. Anesthesiology. 2012, 117: 898-904. 10.1097/ALN.0b013e318266c6df.CrossRef
47.
go back to reference Eriksson C, Gustavsson A, Kronvall T, Tysk C: Hepatotoxicity by bosentan in a patient with portopulmonary hypertension: a case-report and review of the literature. J Gastrointestin Liver Dis. 2011, 20: 77-80. Eriksson C, Gustavsson A, Kronvall T, Tysk C: Hepatotoxicity by bosentan in a patient with portopulmonary hypertension: a case-report and review of the literature. J Gastrointestin Liver Dis. 2011, 20: 77-80.
Metadata
Title
Management of pulmonary vasodilator therapy in patients with pulmonary arterial hypertension during critical illness
Authors
Katie M Muzevich
Hadi Chohan
Daniel C Grinnan
Publication date
01-10-2014
Publisher
BioMed Central
Published in
Critical Care / Issue 5/2014
Electronic ISSN: 1364-8535
DOI
https://doi.org/10.1186/s13054-014-0523-z

Other articles of this Issue 5/2014

Critical Care 5/2014 Go to the issue